Maxim lowered the firm’s price target on Autonomix (AMIX) to $2 from $5 and keeps a Buy rating on the shares. The company’s Q3 results were slightly better than expected, though the firm is cutting its price target on expected share dilution from a likely capital raise, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMIX:
- Autonomix: Advancing Microchip-Based Cancer Pain Platform with Clear Regulatory Path and Attractive Risk‑Reward
- Autonomix announces final clinical data on pain mitigation in pancreatic cancer
- Autonomix Medical Receives Nasdaq Minimum Bid Price Notice
- Autonomix Medical reports promising pain relief in pancreatic cancer
- Autonomix showcases PoC study clinical data at 2026 ASCO Symposium